• Ven. Dic 13th, 2024

pancreatic sislet cells

  • Home
  • Understanding the benefits of GLP-1 drugs beyond obesity

Understanding the benefits of GLP-1 drugs beyond obesity

In a Perspective, Daniel Drucker highlights the growing body of evidence that hints at the potential of glucagon-like peptide-1 (GLP-1)-based medications in treating conditions other than diabetes and obesity, including…